These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36648148)

  • 21. Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma.
    Finotello R; Schiavo L; Ressel L; Frohmader A; Silvestrini P; Verin R
    J Comp Pathol; 2019 Jul; 170():1-9. PubMed ID: 31375151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical detection of uroplakin III, cytokeratin 7, and cytokeratin 20 in canine urothelial tumors.
    Ramos-Vara JA; Miller MA; Boucher M; Roudabush A; Johnson GC
    Vet Pathol; 2003 Jan; 40(1):55-62. PubMed ID: 12627713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
    Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
    Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection of Copy Number Imbalance in Canine Urothelial Carcinoma With Droplet Digital Polymerase Chain Reaction.
    Mochizuki H; Shapiro SG; Breen M
    Vet Pathol; 2016 Jul; 53(4):764-72. PubMed ID: 26574558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tyrosine kinase receptor status in endometrial stromal sarcoma: an immunohistochemical and genetic-molecular analysis.
    Cossu-Rocca P; Contini M; Uras MG; Muroni MR; Pili F; Carru C; Bosincu L; Massarelli G; Nogales FF; De Miglio MR
    Int J Gynecol Pathol; 2012 Nov; 31(6):570-9. PubMed ID: 23018215
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro.
    Milovancev M; Helfand SC; Marley K; Goodall CP; Löhr CV; Bracha S
    BMC Vet Res; 2016 Jun; 12():85. PubMed ID: 27259510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.
    Wilczynski SP; Chen YY; Chen W; Howell SB; Shively JE; Alberts DS
    Hum Pathol; 2005 Mar; 36(3):242-9. PubMed ID: 15791568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canine urothelial carcinoma: a pilot study of microRNA detection in formalin-fixed, paraffin-embedded tissue samples and in normal urine.
    Varvil MS; Clark SL; Bailey TW; Ramos-Vara JA; Santos APD
    J Vet Diagn Invest; 2024 Jan; 36(1):70-77. PubMed ID: 38014733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of genomic mutation and immunohistochemistry of platelet-derived growth factor receptors in canine vascular tumours.
    Abou Asa S; Mori T; Maruo K; Khater A; El-Sawak A; Abd el-Aziz E; Yanai T; Sakai H
    Vet Comp Oncol; 2015 Sep; 13(3):237-45. PubMed ID: 23611531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of c-kit and platelet-derived growth factor receptors in ovarian granulosa cell tumors.
    Rocconi RP; Matthews KS; Kimball KJ; Conner MG; Baker AC; Barnes MN
    Reprod Sci; 2008 Sep; 15(7):673-7. PubMed ID: 18492696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
    Bourn J; Cekanova M
    Drug Des Devel Ther; 2018; 12():1727-1742. PubMed ID: 29942116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.
    Mohammed SI; Craig BA; Mutsaers AJ; Glickman NW; Snyder PW; deGortari AE; Schlittler DL; Coffman KT; Bonney PL; Knapp DW
    Mol Cancer Ther; 2003 Feb; 2(2):183-8. PubMed ID: 12589035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.
    Jansson S; Bendahl PO; Grabau DA; Falck AK; Fernö M; Aaltonen K; Rydén L
    PLoS One; 2014; 9(7):e102176. PubMed ID: 25025175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue S100/calgranulin expression and blood neutrophil-to-lymphocyte ratio (NLR) in dogs with lower urinary tract urothelial carcinoma.
    Weinekötter J; Gurtner C; Protschka M; von Bomhard W; Böttcher D; Schlinke A; Alber G; Rösch S; Steiner JM; Seeger J; Oechtering GU; Heilmann RM
    BMC Vet Res; 2022 Nov; 18(1):412. PubMed ID: 36411489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.
    Song SH; Jeong IG; You D; Hong JH; Hong B; Song C; Jung WY; Cho YM; Ahn H; Kim CS
    Int J Clin Exp Pathol; 2014; 7(11):7681-9. PubMed ID: 25550804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vascular endothelial growth factor receptor 2, but not S100A4 or S100A6, correlates with prolonged survival in advanced urothelial carcinoma.
    Shah CH; Viktorsson K; Kanter L; Sherif A; Asmundsson J; Rosenblatt R; Lewensohn R; Ullén A
    Urol Oncol; 2014 Nov; 32(8):1215-24. PubMed ID: 24880461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of the current standing of microRNA expression in canine urothelial carcinoma.
    Varvil MS; Dos Santos AP
    Am J Vet Res; 2024 Oct; 85(10):. PubMed ID: 39047791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.